Janssen Biotech Inc.

06/29/2022 | Press release | Distributed by Public on 06/29/2022 07:32

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma